December 27, 2022 – Johnson & Johnson recently announced it has completed its acquisition of Abiomed, Inc. Abiomed is now part of Johnson & Johnson and will operate as a standalone business within Johnson & Johnson’s MedTech segment.
Abiomed manufactures medical technology that provides circulatory and oxygenation devices designed to assist or replace the life-sustaining pumping functions of the failing heart. According to a press release, Abiomed’s patient-first philosophy aligns with the mission and vision for Johnson & Johnson.
Ashley McEvoy, Executive Vice President and Worldwide Chairman of MedTech at Johnson & Johnson, said, “The completion of this acquisition allows Johnson & Johnson MedTech to expand our portfolio in the high growth cardiovascular markets, adding solutions for heart recovery to our global market leading Biosense Webster electrophysiology business. Fueled by Johnson & Johnson’s global scale and commercial and clinical strength, we are excited to explore the opportunities and possibilities ahead to reach even more patients with critical unmet need.”